Diakine-DK210 (EGFR) is under clinical development by Deka Biosciences and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 60% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Diakine-DK210 (EGFR)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Diakine-DK210 (EGFR) overview
Diakine-DK210 (EGFR) is under development for the treatment of solid tumors including kidney cancer (Renal Cell Cancer), skin cancer, non-small cell lung cancer, bladder cancer, pancreatic cancer, colorectal cancer, head and neck cancer and solid tumor. It s being administered through subcutaneous route. The therapeutic candidate comprises of coupled interleukin-2 and interleukin-10 variants that acts by targeting EGFR. Drug candidate is being developed based on Diakine platform.
Deka Biosciences overview
Deka Biosciences is a pharmaceutical company which is developing next generation targeted cytokine therapies to treat cancer and inflammatory diseases. The company is headquartered in Germantown, Maryland, the US.
For a complete picture of Diakine-DK210 (EGFR)’s drug-specific PTSR and LoA scores, buy the report here.